TG Therapeutics soared 17% after earnings surprise

Here’s what happened to TG Therapeutics.

Mar 3, 2025 - 23:13

TG Therapeutics soared 17% after earnings surprise

TG Therapeutics (TGTX) stock surged 17% on Mar. 3 after the company reported revenue that topped Wall Street estimates.

The company reported Q4 earnings per share of 15 cents, falling short of the consensus estimate of 17 cents. However, revenue for the quarter came in at $108.19 million, surpassing the expected $100.67 million by 7.5%.

TG Therapeutics projects a full-year revenue of $540 million for 2025, slightly ahead of the consensus forecast of $534.45 million. It reported 2024 revenue of $329 million.

Full-year operating expense is expected to be about $300 million, excluding non-cash compensation, the company said.

"2024 was a year of significant outperformance and growth for TG," said Michael Weiss, TG Therapeutics's CEO.

TG Therapeutics surged 76.23% in 2024.

The company turned to profits in mid-2024, when it posted a 4-cent gain per share for Q2, while analysts had expected a 2-cent loss.

What does TG Therapeutics do?

TG Therapeutics is a biopharmaceutical company that sells a multiple sclerosis (MS) treatment called Briumvi, which has driven its revenue growth.

Briumvi's U.S. net product revenue reached $310 million in 2024, representing an impressive 250% year-over-year growth.

Weiss highlighted the strong adoption of Briumvi for adult patients with relapsing forms of multiple sclerosis, "which surpassed our initial expectations."

"We made meaningful progress in strengthening our Briumvi patent portfolio through 2042, launching new clinical trials, including for subcutaneous Briumvi, and advancing our pipeline. These accomplishments provide a solid foundation as we look toward continued success in 2025."

TG Therapeutics is working to develop a subcutaneous, or under-the-skin, version of Briumvi.

The current version of Briumvi is given intravenously or by infusion into the bloodstream. The subcutaneous version could allow at-home self-administration, making it more convenient for patients.

The company said the new version of Briumvi “will be attractive to patients and healthcare providers,” Weiss said in a January press release.

Multiple Sclerosis News Today reported that TG Therapeutics has set the list price for Briumvi at $59,000 per year, which is the lowest list price for any branded MS therapy currently on the market.

“From really the beginning of this company, we’ve talked about trying to be responsible in pricing drugs,” Weiss told Multiple Sclerosis News Today.

Analysts raised TGTX stock price target

In January, Bank of America raised its price target on TG Therapeutics to $10 from $9 and maintained an underperform rating, thefly.com reported.

While political and rate uncertainty continues to be an overhang, the firm views the health of the Biopharma sector as "markedly improved from 2022 lows."

Bank of America continues to like late-stage clinical or early launch stories, although it sees Phase 1 clinical programs with derisking data and near-term catalysts as "increasingly areas of investor focus."

Last November, JPMorgan said it saw an increasingly attractive setup for TG Therapeutics stock in the mid-term.

The firm raised its price target on TG Therapeutics to $43 from $30 and reiterated an overweight rating.

More Health Care:

One of the major catalysts for growth JPMorgan considered was the potential launch of Briumvi SC (subcutaneous version) in early 2025.

JPMorgan predicts Briumvi SC could ultimately capture 35% of the at-home anti-CD20 multiple sclerosis treatment market.

The stock closed at $34.42 on Mar. 3.